文献速递睡眠呼吸障碍

优化NIV医保覆盖:中枢性睡眠呼吸暂停患者技术专家小组报告

Optimal NIV Medicare Access Promotion: Patients With Central Sleep Apnea: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society.
PubMed 文献 · Chest · 2021-07-30

本文总结了中枢性睡眠呼吸暂停(CSA)技术专家小组的建议,指出现行医保覆盖标准与指南治疗推荐不一致,例如CPAP和氧疗被推荐却未覆盖,而无备用频率的双水平正压通气可能加重CSA却可覆盖。小组提出简化覆盖定义、移除低通气术语、覆盖所有有效疗法及允许设备转换等建议。

要点

  • 现行医保覆盖标准与CSA指南推荐不一致,CPAP和氧疗被推荐但未覆盖。
  • 无备用频率的BPAP可能加重CSA,却可作为OSA覆盖疗法。
  • 建议简化CSA覆盖定义、移除低通气术语、覆盖所有有效疗法并允许设备转换。

核心结论

  • 现行CSA医保覆盖标准与指南推荐不匹配,需进行多项修改以优化患者获得有效治疗。

研究设计与样本

  • 本文为美国胸科医师学会、美国呼吸治疗协会、美国睡眠医学会和美国胸科学会联合召集的CSA技术专家小组报告。

主要发现

  • CPAP和氧疗被推荐用于CSA但未覆盖。
  • 无备用频率的BPAP可能加重CSA,却可作为OSA覆盖疗法。
  • 要求CPAP或BPAP自发模式下近乎消除阻塞事件的严格覆盖标准可能妨碍使用更有效的BPAP备用频率或自适应伺服通气。
  • CSA是动态疾病,可能需随时间切换设备,如从BPAP备用频率切换至自适应伺服通气可能不被覆盖。

关键数值与推荐

  • 建议单一简化的CSA初始和持续覆盖定义,与OSA对齐。
  • 建议从CSA覆盖标准中移除低通气术语。
  • 建议覆盖所有有效CSA疗法,包括氧疗和所有伴或不伴备用频率或伺服机制的正压通气设备。
  • 建议对一种PAP设备反应欠佳的患者,允许加用氧疗或更换为不同功能设备(如测试有效)。

临床怎么用

  • 临床医生应了解现行覆盖标准可能限制CSA患者获得指南推荐治疗。
  • 在处方CSA治疗时,需考虑设备覆盖情况并可能需申请例外或切换设备。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This document summarizes suggestions of the central sleep apnea (CSA) Technical Expert Panel working group. This paper shares our vision for bringing the right device to the right patient at the right time. For patients with CSA, current coverage criteria do not align with guideline treatment recommendations. For example, CPAP and oxygen therapy are recommended but not covered for CSA. On the other hand, bilevel positive airway pressure (BPAP) without a backup rate may be a covered therapy for OSA, but it may worsen CSA. Narrow coverage criteria that require near elimination of obstructive breathing events on CPAP or BPAP in the spontaneous mode, even if at poorly tolerated pressure levels, may preclude therapy with BPAP with backup rate or adaptive servoventilation, even when those devices provide demonstrably better therapy. CSA is a dynamic disorder that may require different treatments over time, sometimes switching from one device to another; an example is switching from BPAP with backup rate to an adaptive servoventilation with automatic end-expiratory pressure adjustments, which may not be covered. To address these challenges, we suggest several changes to the coverage determinations, including: (1) a single simplified initial and continuing coverage definition of CSA that aligns with OSA; (2) removal of hypoventilation terminology from coverage criteria for CSA; (3) all effective therapies for CSA should be covered, including oxygen and all PAP devices with or without backup rates or servo-mechanisms; and (4) patients shown to have a suboptimal response to one PAP device should be allowed to add oxygen or change to another PAP device with different capabilities if shown to be effective with testing.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Morgenthaler TI, Malhotra A, Berry RB, et al. Optimal NIV Medicare Access Promotion: Patients With Central Sleep Apnea: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society. Chest. 2021. PMID: 34339687. doi:10.1016/j.chest.2021.07.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。